Opendata, web and dolomites

BREATH

BREATH: Biomarkers for Respiratory diseases detected in Exhaled Air through a new Technological instrument for research and Healthcare markets.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BREATH project word cloud

Explore the words cloud of the BREATH project. It provides you a very rough idea of what is the project "BREATH" about.

patient    stage    time    companies    asthma    particles    initially    stages    substantial    service    stand    cancer    phase1    diagnosis    quality    380    socio    outcome    kits    chronic    completely    services    repeatable    breath    airways    easily    chemical    biomarkers    deaths    faster    academia    fundamentally    diagnosed    breathing    difficult    detect    exhaled    once    pexa    feasibility    provides    checking    actively    diseases    commercial    alone    disease    device    each    disposable    responsible    painful    innovation    competitiveness    burden    respiratory    quantitative    instrument    pulmonary    professionals    usually    diagnostic    healthcare    assessing    collect    pharmaceutical    small    prove    designing    health    risk    consists    air    extensive    manufacture    invasive    obstructive    billion    clients    reliability    market    lung    alternative    profitability    tuberculosis    million    economic    brings    patients    figure    diagnose   

Project "BREATH" data sheet

The following table provides information about the project.

Coordinator
PEXA AB 

Organization address
address: ERIK DAHLBERGSGATAN 11 A
city: GOTEBORG
postcode: 411 26
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website http://pexa.se/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology)
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-11-01   to  2017-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PEXA AB SE (GOTEBORG) coordinator 50˙000.00

Map

Leaflet | Map data © OpenStreetMap contributors, CC-BY-SA, Imagery © Mapbox

 Project objective

Each year in Europe, lung diseases are responsible of more than one million deaths and extensive costs estimated at €380 billion. These respiratory diseases, such as chronic obstructive pulmonary disease, lung cancer, asthma and tuberculosis, are very difficult to detect and usually diagnosed in late-stages once there is a significant burden of disease within them. BREATH project consists to develop, manufacture and market a research instrument to study and to diagnose respiratory diseases. The concept is based on a completely new method to collect and analyse particles via exhaled air in the small airways to easily identify chemical changes and potential biomarkers for respiratory diseases. The PExA method has the potential to fundamentally change the way lung diseases are diagnosed and treated today by offering a best alternative of the existing methods on market, which brings a substantial commercial potential. By doing a simple breathing test and without any potential risk for the patients, PExA's instrument provides a quantitative, reliable, user friendly, non-invasive, less painful, faster, repeatable method for early-stage diagnosis. PExA's clients are all those who are currently actively looking for biomarkers to figure out the patient's health conditions such as lung researchers and healthcare professionals within health services, academia and pharmaceutical companies initially in the EU and then the US. The objectives of BREATH project Phase1 are to: (1) prove through a feasibility study the potential to develop a real-time and stand-alone analysis/diagnostic device; (2) enhance the competitiveness and profitability of the service by improving the quality and reliability of the system via (i) the checking system, (ii) designing and developing our own disposable kits. The outcome will be a feasibility study assessing the socio-economic, commercial and technical aspects of the innovation that will be used to define the activities of Phase II.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BREATH" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BREATH" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.4.;H2020-EU.2.3.1.)

FlexiBiome (2018)

Next Generation Microbiome Platform

Read More  

N-IF (2017)

The N-IF mouse – a new and unique fibrosis model for preclinical efficacy studies

Read More  

SINUSLIGHT (2018)

Laser-spectroscopic sensing device for diagnostic assessment of sinusitis

Read More